Cargando…
The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue
BACKGROUND: Erectile dysfunction (ED) is a relatively frequent disease that negatively impacts the overall quality of life, well‐being, and relationships. Although the use of phosphodiesterase 5 inhibitors (PDE5is) has revolutionized the treatment of ED, a high percentage of ED patients discontinue...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790582/ https://www.ncbi.nlm.nih.gov/pubmed/31350821 http://dx.doi.org/10.1111/andr.12683 |
_version_ | 1783458802696192000 |
---|---|
author | Zucchi, A. Costantini, E. Scroppo, F. I. Silvani, M. Kopa, Z. Illiano, E. Petrillo, M. G. Cari, L. Nocentini, G. |
author_facet | Zucchi, A. Costantini, E. Scroppo, F. I. Silvani, M. Kopa, Z. Illiano, E. Petrillo, M. G. Cari, L. Nocentini, G. |
author_sort | Zucchi, A. |
collection | PubMed |
description | BACKGROUND: Erectile dysfunction (ED) is a relatively frequent disease that negatively impacts the overall quality of life, well‐being, and relationships. Although the use of phosphodiesterase 5 inhibitors (PDE5is) has revolutionized the treatment of ED, a high percentage of ED patients discontinue PDE5i treatment. OBJECTIVES: (i) To analyze the reasons for patient dissatisfaction leading to PDE5i discontinuation; (ii) analyze the pharmacokinetics of new formulations focusing on the time needed to reach an effective plasma concentration of PDE5is (T(onset)) following drug intake; and (iii) summarize the physicochemical properties of sildenafil to understand which excipients may increase the absorption rate. MATERIAL AND METHODS: An online PubMed literature search was conducted to identify English language publications from inception to January 2019. RESULTS: The main reasons for patient dissatisfaction when using PDE5is on demand are the relatively long T(onset) after taking vardenafil and sildenafil, including formulations such as film‐coated tablets, fine granules, orally disintegrating tablets (ODTs), and oral thin films (ODFs). The relatively long T(onset), further worsened when accompanied by eating, highlights the following: (i) the need for planning intercourse, determining partner‐related issues; (ii) issues when having sex before the maximum effect of the drug; and (iii) lower drug‐related placebo effects. Some data suggest that sildenafil is a ‘difficult’ molecule, but T(onset) can be improved following absorption by buccal mucosa using appropriate excipients. CONCLUSIONS: We conclude that several ODT and ODF formulations can improve the ‘discretion’ issue because they are taken without water, but they have similar pharmacokinetics to corresponding film‐coated tablet formulations. One ODF formulation of sildenafil was characterized by a shorter T(onset) and could potentially increase patient satisfaction following treatment. However, more clinical studies are needed to confirm the findings. Surfactants and ascorbic acid appear to be crucial excipients for achieving a high absorption rate, but more studies are needed. |
format | Online Article Text |
id | pubmed-6790582 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67905822019-10-18 The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue Zucchi, A. Costantini, E. Scroppo, F. I. Silvani, M. Kopa, Z. Illiano, E. Petrillo, M. G. Cari, L. Nocentini, G. Andrology Review Articles BACKGROUND: Erectile dysfunction (ED) is a relatively frequent disease that negatively impacts the overall quality of life, well‐being, and relationships. Although the use of phosphodiesterase 5 inhibitors (PDE5is) has revolutionized the treatment of ED, a high percentage of ED patients discontinue PDE5i treatment. OBJECTIVES: (i) To analyze the reasons for patient dissatisfaction leading to PDE5i discontinuation; (ii) analyze the pharmacokinetics of new formulations focusing on the time needed to reach an effective plasma concentration of PDE5is (T(onset)) following drug intake; and (iii) summarize the physicochemical properties of sildenafil to understand which excipients may increase the absorption rate. MATERIAL AND METHODS: An online PubMed literature search was conducted to identify English language publications from inception to January 2019. RESULTS: The main reasons for patient dissatisfaction when using PDE5is on demand are the relatively long T(onset) after taking vardenafil and sildenafil, including formulations such as film‐coated tablets, fine granules, orally disintegrating tablets (ODTs), and oral thin films (ODFs). The relatively long T(onset), further worsened when accompanied by eating, highlights the following: (i) the need for planning intercourse, determining partner‐related issues; (ii) issues when having sex before the maximum effect of the drug; and (iii) lower drug‐related placebo effects. Some data suggest that sildenafil is a ‘difficult’ molecule, but T(onset) can be improved following absorption by buccal mucosa using appropriate excipients. CONCLUSIONS: We conclude that several ODT and ODF formulations can improve the ‘discretion’ issue because they are taken without water, but they have similar pharmacokinetics to corresponding film‐coated tablet formulations. One ODF formulation of sildenafil was characterized by a shorter T(onset) and could potentially increase patient satisfaction following treatment. However, more clinical studies are needed to confirm the findings. Surfactants and ascorbic acid appear to be crucial excipients for achieving a high absorption rate, but more studies are needed. John Wiley and Sons Inc. 2019-07-26 2019-11 /pmc/articles/PMC6790582/ /pubmed/31350821 http://dx.doi.org/10.1111/andr.12683 Text en © 2019 The Authors. Andrology published by John Wiley & Sons Ltd on behalf of American Society of Andrology and European Academy of Andrology This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Articles Zucchi, A. Costantini, E. Scroppo, F. I. Silvani, M. Kopa, Z. Illiano, E. Petrillo, M. G. Cari, L. Nocentini, G. The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue |
title | The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue |
title_full | The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue |
title_fullStr | The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue |
title_full_unstemmed | The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue |
title_short | The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue |
title_sort | first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790582/ https://www.ncbi.nlm.nih.gov/pubmed/31350821 http://dx.doi.org/10.1111/andr.12683 |
work_keys_str_mv | AT zucchia thefirstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue AT costantinie thefirstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue AT scroppofi thefirstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue AT silvanim thefirstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue AT kopaz thefirstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue AT illianoe thefirstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue AT petrillomg thefirstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue AT caril thefirstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue AT nocentinig thefirstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue AT zucchia firstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue AT costantinie firstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue AT scroppofi firstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue AT silvanim firstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue AT kopaz firstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue AT illianoe firstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue AT petrillomg firstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue AT caril firstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue AT nocentinig firstgenerationphosphodiesterase5inhibitorsandtheirpharmacokineticissue |